May 05, 2022
Article
High adherence to treatment is a key first step toward better patient outcomes, including sustained disease control or remission.
March 10, 2022
Insurers, accountable care organizations, and manufacturers increasingly look for demonstrable clinical outcomes as proof for reimbursement or access to limited distribution networks.
March 07, 2022
Amidst the frenzy of blockbuster medicines, the connection between the high price of a drug and how well it works is becoming looser.
March 04, 2022
Upadacitinib (Rinvoq) is a Janus kinase (JAK) inhibitor being investigated to treat rheumatoid arthritis, Crohn disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis, axial SpA giant cell arteritis, and Takayasu arteritis
February 07, 2022
Patients with rheumatoid arthritis taking at least 3 targeted therapies were found to have a greater risk of developing herpes zoster.
January 05, 2022
Agency greenlights secukinumab’s use for pediatric Treatment of enthesitis-related arthritis and Juvenile psoriatic arthritis.
December 17, 2021
Abatacept is also approved for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, and moderate to severe polyarticular juvenile idiopathic arthritis for children 2 years of age and older.
November 18, 2021
Olumiant shows favorable long-term safety profile in rheumatoid arthritis.
November 15, 2021
Study evaluates the safety profile of upadacitinib at 15 mg and 30 mg once daily for patients with moderately to severely active rheumatoid arthritis.
November 02, 2021
Agency gives green light to supplemental new drug application for repository corticotropin injection.
